3166-98-1

Upstream product

• 91062-39-4 1-(Bromomethyl)-4-propylbenzene 
• 143-33-9 sodium cyanide 
• 52710-27-7 4-propylbenzoyl chloride 
• 28785-06-0 4-n-propylbenzaldehyde 
• 82657-70-3 4-n-propylbenzyl alcohol 
• 1093190-16-9 [2-(4-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)ethynyl]trimethylsilane 
• 275386-60-2 4-(hydroxymethyl)-1-(trimethylsilylethynyl)benzene 
• 1093190-17-0 tert-butyl[(4-ethynylphenyl)methoxy]dimethylsilane 
• 773837-37-9 sodium cyanide 
• 1360803-33-3 1-(iodomethyl)-4-propylbenzene 
• 1224716-84-0 4-propylbenzyl methanesulfonate 
• 1360803-31-1 tert-butyldimethyl((4-(prop-1-yn-1-yl)benzyl)oxy)silane 
• 1360803-32-2 tert-butyldimethyl((4-propylbenzyl)oxy)silane 
• 619-42-1 4-methoxycarbonylphenyl bromide 

Downstream Products

• 1360803-35-5 methyl 2-(N-(4-propylbenzyl)-2-(4-propylphenyl)acetamido)acetate 
• 1360803-36-6 2-(N-(4-propylbenzyl)-2-(4-propylphenyl)acetamido)acetic acid 
• 26114-12-5 2-(4-propylphenyl)acetic acid 
• 950508-67-5 2-(4-n-propylphenyl)-3-phenylpropan-2-one 

Relevant academic research and scientific papers

CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES

The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, RA1, RA2, RC and RD are as defined herein.

LABELING AGENT AND AMINO ACID SEQUENCE USING SAME, AND METHOD FOR PERFORMING SIMULTANEOUS QUANTITATIVE ANALYSIS OF MULTIPLE PROTEINS

The present invent ion provides a compound that can utilize hydrogen isotope and, at the same time, can quantify multiplexed samples at one time, as well as decreasing the cost for synthesis of the labeling agent. In addition, the present invention provid

Making a difference on excited-state chemistry by controlling free space within a nanocapsule: Photochemistry of 1-(4-alkylphenyl)-3-phenylpropan-2-ones

The free space within a reaction cavity plays a determining role during the excited-state reaction of 1-(4-alkylphenyl)-3-phenylpropan-2-ones included within a capsule formed by two molecules of a deep cavity cavitand. By controlling the free space within the reaction cavity through remote alkyl substitution on the reactant ketone it is possible to control the yield of the rearrangement product shown above.

Benzylimidazolines as h5-HT(1B/1D) serotonin receptor ligands: A structure-affinity investigation

Benzylimidazolines may represent a class of 5-HT(1D) ligands that has yet to be exploited. On the basis of a previous report that the 2- (substituted-benzyl)imidazoline α-adrenergic agonist oxymetazoline (8) binds with high affinity at calf brain 5-HT(1D) receptors, we explored the structure-affinity relationships of a series of related derivatives. Each of the aromatic substituents was removed and then reinstated in a systematic manner to determine the influence of the individual substituents on binding. It was found that all of the aromatic substituents of 8 act in concert to impart high affinity. However, although the 3-hydroxy group could be removed without significantly reducing affinity for h5-HT(1D) (i.e., human 5- HT(1Dα)) receptors, this modification reduced h5-HT(1B) (i.e., human 5- HT(1Dβ)) receptor affinity by nearly 50-fold. The 2,6-dimethyl groups also contribute to binding but seem to play a greater role for h5-HT(1B) binding than h5-HT(1D) binding. With the appropriate structural modifications, several compounds were identified that display 20- to > 100-fold selectivity for h5-HT(1D) versus h5-HT(1B) receptors. Preliminary functional data suggest that these compounds behave as agonists. Given that 5-HT(1D) agonists are currently being explored for their antimigraine action and that activation of h5-HT(1B) receptors might be associated with cardiovascular side effects, h5- HT(1D)selective agents may offer a new lead for the development of therapeutically efficacious agents.